our approach to Personalized Cancer Therapy

Many thanks to the team and to the patients that helped created this first video version of our vision for personalized cancer therapy.  The approach will probably be moved from canine patients to human patients in the context of relapsed disease.  It's certainly something we are moving ahead as quickly and as carefully as we can.  A high resolution of our video can also be found here.  
  

DVM360 on Canine Osteosarcoma Trial

For more on the OHSU - OSU collaboration, click here .
  

ABC2 Summit in Sausalito

The last 2 days leaders in glioblastoma research have met in a special, collaboration-promoting summit sponsored by Accelerate Brain Cancer Cure (ABC2).  Highlights include understanding the influence of metabolism on glioblastoma tumor cell fitness, the mechanism of action of thalidomide, and more.  By far, the best aspect of this project was the community involvement (hence, accountability for collaboration) and the industry - academic interface that this environment creates.  A very significant industry interest was expressed in DIPG (pontine gliomas).  More news to come...

Many thanks to Max & David of ABC2 for creating such a rich environment for collaboration.  To learn about the life of Dan Case and the creation of ABC2, click here.

 

Rhabdomyosarcoma Research presented in Ascona

We are grateful to Denis Guttridge (Ohio State), David Glass (Novartis) and Markus Ruegg (University of Basel) for the opportunity to present our work on the epigenetic determinates of rhabdomyosarcoma at the 2011 International Conference on Molecular Mechanisms of Muscle Growth and Wasting in Health and Disease.  Our laboratory's work was very well received, and new collaborations were established that take us into new, exciting multidisciplinary areas.  
  
[ The conference was sited at Centro Stefano Franscini in Ascona, Switzerland (pictured). ]

Personalized Medicine Talk with Georgetown Colleagues

We are grateful to Dr. Aykut Uren and colleagues including Todd Waldman and Jeff Toretsky for the opportunity to present our research and approaches to personalized cancer therapy as part of the  the Georgetown University Hospital/Lombardi Cancer Center visiting professorship series.  The ideas exchanged bring both groups closer to our goal of improving survival for the 1 in 5 children for which current therapy is yet not sufficient for long term survival.    

Update on the Personalized Cancer Therapy Trial - for Canine Osteosarcoma

Congratulations to Lara on an excellent research-in-progress presentation at the Annual OHSU-DCH Pediatric Fellows Research Conference.  This Phase II clinical trial for dogs with osteosarcoma opened 2 weeks ago.  The early success of this collaboration is a large part attributable to the strong collaboration with Dr. Bernard Seguin at Oregon State University Veterinary Hospital and lab members and alumni, Jinu and (especially) Nicolle, respectively.  

Scott Carter Foundation Big Show!

Last night in Tulsa was the Scott Carter Foundation Big Show! that precedes the annual golf tournament fundraiser.  Scott was a young boy who had osteosarcoma, but without regard for himself he was passionate that other children like his friend Addie should have better available treatments.  He created an effort to raise money for childhood cancer research, and in his memory Scott's family and community annually raise funds that support the training of new research scientists, which have included Charles more than a decade ago, as well as our own lab's recent graduates: Koichi Nishijo, Jinu Abraham and Nicolle Hofmann.  We are grateful to the Scott Carter Foundation for their support of our trainees and our research on sarcomas, including osteosarcoma.
 
[ right, John Grant mc'g the auction; left, Charles and Paul 'Ole Dad' Compton, Scott's grandfather. ]